Objectives: This study describes the implementation of a training course that aimed to increase the competency of undergraduate students of Korean medicine at a single college to obtain informed consent and perform bee venom acupuncture using an objective structured clinical examination (OSCE).Methods: We developed and implemented a short training course for 111 fourth-year students of Korean medicine during their clinical rotation at the Department of Acupuncture and Moxibustion Medicine. Lectures were conducted on the effects of and hypersensitivity reactions to bee venom acupuncture, obtaining informed consent, performing skin test and bee venom acupuncture. Due to the COVID-19 pandemic, some students were offered online lectures, and some could not experience the performance of OSCE in person. A survey with 16 closed and three open questions was used to investigate self-efficacy, opinions about the online lectures, and the OSCE.Results: Out of 111 questionnaires, 104 were completed (94%). Students were generally satisfied with the online lectures and OSCE. For the subjective questionnaire about what was helpful in the training of bee venom acupuncture techniques and OSCE, the authenticity of the teaching method was recorded the highest.Conclusions: This study showed that online lectures were effective in teaching clinical skills of Korean Medicine. It is necessary to produce standard educational materials for clinical skills of Korean Medicine, and studies to analyze the reliability and validity of OSCE are needed.
Background: The aim of this pilot study was to assess the safety and dosing of scolopendrid pharmacopuncture (SPP).Methods: A total of 40 healthy Sprague-Dawley rats (males and 20 females 20) were selected following a 7-day inspection and acclimation period. SPP was administered via intramuscular injection, over a 2-week period using 3 doses including a high-dose [0.84 mg of scolopendrid per kg of body weight (BW)], a meddose (0.42 mg/kg BW), and a low-dose (0.21 mg/kg BW). The control group was injected with sterile water into the muscles. Unusual changes caused by administration of the test substance were observed. Weight, feed intake, organ weight, and hematological examinations were compared among the groups. Using the SPSS statistical program, Levene’s test was performed to evaluate the homogeneity of variances, and a one-way ANOVA test was subsequently performed to assess the significance between each test group.Results: During the experiment no animals died. Weight change, food consumption, organ weight, hematological test, and blood biochemical tests showed no significant differences in the treatment groups compared to controls.Conclusion: No toxicological changes related to the administration of test substances were observed. Therefore, the LD50 (lethal-dose that kills 50%) of scolopendrid pharmacoupuncture in rats was greater than 0.84 mg/kg.
Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive muscle weakness and paralysis, with respiratory failure being the leading cause of death. Mecasin (KCHO-1), a standardized botanical extract, has demonstrated neuroprotective and anti-neuroinflammatory effects in preclinical studies. A 12-week phase IIa trial suggested a potential benefit in slowing functional decline. This phase IIb trial evaluated the efficacy and safety of Mecasin over 24 weeks, including respiratory-related outcomes. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial, 50 patients were randomized to receive Mecasin (2.4 g/day) or placebo for 24 weeks, with both groups receiving riluzole (100 mg/day). Forty-three patients were included in the efficacy analysis. The primary endpoint was change in the Korean version of the ALS Functional Rating Scale-Revised (K-ALSFRS-R) total score. Respiratory-related assessments included orthopnea, FEV1/FVC, and end-tidal CO2, alongside safety evaluations. Results: At week 24, K-ALSFRS-R changes were −3.65 and −3.74 points in the Mecasin and placebo groups, respectively, with no significant between-group difference (estimated difference, 0.27; 90% CI, −1.80 to 2.33; p = 0.4146). Significant between-group differences were observed in FEV1/FVC (7.69 percentage points; p = 0.0036) and end-tidal CO2 (−3.92 mmHg; p = 0.0076). Linear mixed-effects models showed significant group-by-visit interactions for orthopnea (p = 0.0212) and FEV1/FVC (p = 0.0228). Adverse-event frequencies were comparable. Conclusions: Although Mecasin did not show a significant effect on the primary outcome (K-ALSFRS-R total score), the observed differences in respiratory-related outcomes provide a clinical rationale for further investigation in larger trials focusing on respiratory function.